Zachariah DeFilipp, Haesook T Kim, Nikolaos Spyrou, Nikolaos Katsivelos, Steven Kowalyk, Gilbert W Eng, Stelios Kasikis, Rahnuma Beheshti, Janna Baez, Yu Akahoshi, Francis Ayuketang Ayuk, Hannah K Choe, Aaron M Etra, Stephan A Grupp, Elizabeth O Hexner, William J Hogan, Carrie L Kitko, Muna Qayed, Ran Reshef, Ingrid Vasova, Robert Zeiser, Rachel Young, Ernst Holler, James L M Ferrara, Ryotaro Nakamura, John E Levine, Yi-Bin Chen
The significance of biomarkers at second-line treatment for acute graft-versus-host disease (GVHD) is not well characterized. We analyzed clinical data and serum samples at initiation of second-line systemic treatment of acute GVHD from 167 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC) between 2016 and 2021. Sixty-two patients received ruxolitinib-based therapy while 102 received other systemic agents. In agreement with prospective trials, ruxolitinib resulted in higher day 28 (D28) ORR compared to non-ruxolitinib therapies (55% vs 31%, P=0...
April 19, 2024: Blood Advances